De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

ChemPartner PharmaTechLtd Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

ChemPartner PharmaTechLtd heeft een totaal eigen vermogen van CN¥1.4B en een totale schuld van CN¥84.3M, wat de schuld-eigenvermogensverhouding op 5.9% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥2.3B en CN¥858.1M.

Belangrijke informatie

5.9%

Verhouding schuld/eigen vermogen

CN¥84.29m

Schuld

Rente dekkingsratio	n/a
Contant	CN¥318.49m
Aandelen	CN¥1.42b
Totaal verplichtingen	CN¥858.09m
Totaal activa	CN¥2.28b

Recente financiële gezondheidsupdates

Geen updates

Recent updates

ChemPartner PharmaTech Co.,Ltd.'s (SZSE:300149) Price Is Right But Growth Is Lacking After Shares Rocket 51%

Sep 30

Improved Revenues Required Before ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) Stock's 29% Jump Looks Justified

Aug 04

Chempartner Pharmatech Co., Ltd.'s (SZSE:300149) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Mar 08

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CN¥615.1M ) 300149 } overtreffen de korte termijn passiva ( CN¥360.5M ).

Langlopende schulden: De kortetermijnactiva 300149 ( CN¥615.1M ) overtreffen de langetermijnschulden ( CN¥497.6M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 300149 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van 300149 is de afgelopen 5 jaar gedaald van 31.6% naar 5.9%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: Terwijl het verlieslatende 300149 voldoende cash runway heeft voor meer dan 3 jaar, als het zijn huidige positieve vrije kasstroom-niveau behoudt.

Voorspelling contante baan: 300149 is verlieslatend, maar heeft voldoende kasmiddelen voor meer dan 3 jaar, zelfs bij een positieve vrije kasstroom die met 14.6 % per jaar krimpt.

ChemPartner PharmaTechLtd Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

ChemPartner PharmaTech Co.,Ltd.'s (SZSE:300149) Price Is Right But Growth Is Lacking After Shares Rocket 51%

ChemPartner PharmaTech Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: CN¥0.076 loss per share (vs CN¥0.011 profit in 2Q 2023)

Improved Revenues Required Before ChemPartner PharmaTech Co.,Ltd. (SZSE:300149) Stock's 29% Jump Looks Justified

ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 31, 2024

First quarter 2024 earnings released: CN¥0.051 loss per share (vs CN¥0.057 loss in 1Q 2023)

New minor risk - Share price stability

Chempartner Pharmatech Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Chempartner Pharmatech Co., Ltd.'s (SZSE:300149) Share Price Boosted 29% But Its Business Prospects Need A Lift Too

Chempartner Pharmatech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Third quarter 2023 earnings released: CN¥0.048 loss per share (vs CN¥0.13 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.011 (vs CN¥1.90 in 2Q 2022)

Investor sentiment deteriorates as stock falls 15%

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

First quarter 2023 earnings released: CN¥0.057 loss per share (vs CN¥0.019 profit in 1Q 2022)

Investor sentiment deteriorates as stock falls 18%

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.021 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥1.90 (vs CN¥0.007 in 2Q 2021)

Tate & Lyle Investments Limited completed the acquisition of Quantum Hi-Tech (Guangdong) Biological Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149).

Tate & Lyle plc (LSE:TATE) completed the acquisition of Guangdong Quantum Hi-Tech Microecology Medical Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149).

Chempartner Pharmatech Co., Ltd. announced that it expects to receive CNY 300 million in funding

Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 23, 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Chempartner Pharmatech Co., Ltd. to Report Fiscal Year 2021 Results on Apr 30, 2022

Less than half of directors are independent

Tate & Lyle plc (LSE:TATE) signed an agreement to acquire Guangdong Quantum Hi-Tech Microecology Medical Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149) for $237 million.

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings released: EPS CN¥0.021 (vs CN¥0.085 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.007 (vs CN¥0.11 in 2Q 2020)

Investor sentiment improved over the past week

Chempartner Pharmatech Co., Ltd. Announces Final Cash Dividend for 2020, Payable on 1 June 2021

Chempartner Pharmatech Co., Ltd. Approves Cash Dividend for the Year 2020

Investor sentiment improved over the past week

Chempartner Pharmatech Co., Ltd. Announces the Profit Distribution Proposal for 2020

First quarter 2021 earnings released: EPS CN¥0.003 (vs CN¥0.028 loss in 1Q 2020)

New 90-day low: CN¥12.64

New 90-day low: CN¥12.66

Investor sentiment deteriorated over the past week

New 90-day low: CN¥14.46

New 90-day low: CN¥18.29

Third quarter earnings released

New 90-day high - CN¥23.98

First half earnings released

Quantum Hi-Tech (China) Biological Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

New 90-day high - CN¥22.71

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Analyse van de cashflow

Ontdek gezonde bedrijven